Business Context and Reporting Period
Company: Revelation Biosciences, Inc. (REVB)
Filing Type: Form 8-K (Current Report)
Date of Report: July 10, 2026
Event: Adoption of a stockholder rights plan (poison pill) and entry into a Rights Agreement with Continental Stock Transfer & Trust Co.
Key Financial Metrics
This filing is a current report regarding a corporate governance action and does not contain financial performance data. The filing text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material change is the implementation of a stockholder rights plan designed to deter unsolicited takeover attempts. Key terms include:
- Trigger Threshold: An "Acquiring Person" is defined as any entity acquiring 10% or more of outstanding Common Stock (15% for qualifying passive investors filing on Schedule 13G) without Board approval.
- Dividend Declaration: One preferred share purchase right (Right) declared for each outstanding share of Common Stock, payable to stockholders of record on July 21, 2026.
- Exercise Price: Each Right entitles the holder to purchase one one-thousandth of a share of Series B Junior Participating Preferred Stock at $20.00.
- Flip-In Provision: If an Acquiring Person is identified, Rights holders (excluding the Acquiring Person) may purchase Common Stock with a market value of twice the Purchase Price.
- Flip-Over Provision: If the Company is acquired after an Acquiring Person is identified, Rights may be exchanged for discounted stock of the acquiring company.
- Redemption: The Board may redeem Rights at $0.001 per Right at any time before an Acquiring Person emerges.
- Expiration: Rights expire on the first anniversary of the agreement unless ratified by stockholders, in which case they expire on the third anniversary.
Guidance, Outlook, and Risks
Management Commentary: The filing indicates the Board adopted the plan to protect stockholder interests, though specific strategic rationale beyond the standard rights plan mechanics is not detailed in the text provided.
Risks and Contingencies: The plan introduces a contingency where unsolicited acquirers face significant dilution if they cross the 10% ownership threshold without Board approval. The plan may be amended by the Board prior to the emergence of an Acquiring Person.
Investor Verification Checklist
- Verify the Record Date of July 21, 2026, to determine eligibility for the Rights dividend.
- Review the full Rights Agreement (Exhibit 4.1) for specific exceptions to the 10% trigger threshold.
- Monitor for any future press releases regarding stockholder ratification of the Rights Agreement before the first anniversary.
- Check for any subsequent filings indicating the redemption of the Rights or the emergence of an Acquiring Person.